ClinicalTrials.Veeva

Menu

Study Evaluating the MindMotionPRO for Early Post-stroke Upper-limb Rehabilitation (MOVE-Rehab)

M

Mindmaze

Status

Terminated

Conditions

Stroke
Motor Disorders

Treatments

Other: Self-Directed Prescribed Exercises
Device: MindMotionPRO

Study type

Interventional

Funder types

Industry

Identifiers

NCT02688413
MindMaze-2016-RCT01

Details and patient eligibility

About

Randomised controlled multi-centered study using MindMotionPRO, an immersive virtual reality based system for upper limb motor rehabilitation in early post-stroke patients. The study aims to evaluate the ability of MindMotionPRO technology to increase the rehabilitation dose. Effectiveness will be evaluated by validated rehabilitation performance scales. Cost-effectiveness will be assessed by the resource utilization.

Full description

The goal of the study is to show that MindMotionPRO is a tool that allows a patient to increase the amount of rehabilitation therapy performed. This study will measure the rehabilitation dose, as measured by the duration of the rehabilitation session and the number of exercises performed by the patient. The study hypothesis is that patients in the MindMotionPRO group will spend more time performing rehabilitation exercises than in the Self-Directed Prescribed exercises group. The effectiveness of the MindMotionPRO versus Self-Directed Prescribed Exercises will also be measured, based on the change in rehabilitation performance measures. The cost-effectiveness will be measured by the resource utilization, as defined by the time spent by the therapist providing the rehabilitation session.

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male/female > 18 years old
  • First ever unilateral supratentorial ischemic stroke with contralateral upper extremity weakness
  • 1 to 6 weeks post-stroke
  • Able to give informed consent
  • Not participating any other intervention studies
  • Experiencing motor difficulties in using the paretic arm, with a FMA-UE score in the range of 20 to 40 out of 66
  • Stroke severity with NIHSS score between 5 (mild) and 14 (moderate) out of 42
  • The participant is expected to remain available (geographically stable) for 4 months after enrolment.

Exclusion criteria

  • Any medical condition compromising the safety or the ability to take part to the study (such as insufficient vision or hearing, inability to participate to therapy session, inability to communicate, upper limb condition not linked to stroke, uncontrolled blood pressure, uncontrolled diabetes, co-morbidity)
  • Recurrent and moderate to high upper limb pain limiting delivery of rehabilitation dose
  • History of more than one epileptic seizures since stroke onset or uncontrolled epileptic seizure
  • Mild to severe cognitive impairment (Mini mental state exam (MMSE) score < 24/30)
  • Depression (Hospital Anxiety and Depression Scale > 8/21)
  • Moderate to severe hemispatial neglect compromising the ability to take part to the study, as determined by the Bells tests (> 6 errors)
  • Brain stem stroke

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

9 participants in 2 patient groups

MindMotionPRO
Experimental group
Description:
MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
Treatment:
Device: MindMotionPRO
Self-Directed Prescribed Exercises
Active Comparator group
Description:
Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
Treatment:
Other: Self-Directed Prescribed Exercises

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems